The ER (endoplasmic reticulum) is a major protein folding and modification organelle. In its lumen, the ER processes a third of all newly synthesized proteins. To accomplish this task, numerous resident proteins capture the nascent and newly synthesized proteins. The underlying luminal protein-protein interactions, however, are inherently difficult to analyse, mainly due to their transient nature and the rather specialized environment of the ER. To overcome these limitations, we developed a PCA (protein fragment complementation assay) based on the citrine variant of YFP (yellow fluorescent protein). YFP PCA was successfully applied to visualize the protein interactions of the cargo transport receptor ERGIC-53 (endoplasmic reticulum-Golgi intermediate compartment protein of 53 kDa) with its luminal interaction partner MCFD2 (multiple coagulation factor deficiency protein 2) and its cargo proteins cathepsin Z and cathepsin C in a specific manner. With the prospect of screening cDNA libraries for novel protein-protein interactions, YFP PCA is a promising emerging technique for mapping protein interactions inside the secretory pathway in a genome-wide setting.
Introduction
The ER (endoplasmic reticulum) harbours an elaborated machinery of resident proteins involved in folding and modification of newly synthesized proteins. General chaperones prevent the aggregation of unfolded proteins, protein disulfide-isomerases catalyse the formation and isomerization of disulfide bridges, oligosaccharyltransferase adds Nlinked glycans, and lectins such as calnexin and calreticulin control the folding process of glycoproteins [1] . All these events require that the folding and modification machinery of the ER recognizes and captures the corresponding substrate proteins. Which current technique is best suited to elucidate the numerous protein-protein interactions in the lumen of the ER? One has to consider that the ER lumen represents a specialized environment that differs from the cytosol with respect to redox potential, ion concentrations and the accessibility to distinct post-translational modifications such as Nlinked glycosylation. The yeast two-hybrid system [2] , one of the most widely applied techniques in interaction proteomics, is not appropriate to capture luminal protein complexes in most instances, since this technique detects protein-protein interactions in the nucleus of yeast in a reducing environment. MS-based analysis of protein complexes [3] , another commonly used technique, is challenged by the transient nature of luminal protein complexes which are difficult to preserve during affinity-purification procedures. To tackle the difficulties in capturing luminal protein interactions, we successfully developed a PCA (protein fragment complementation assay) [4] for the lumen of the secretory pathway.
PCAs
The general principle of PCA relies on rationally dissecting a reporter protein into two inactive fragments which can reconstitute a functional reporter in vivo if brought into close proximity. Two engineered reporter fragments are fused to two proteins of interest which are then co-expressed in yeast, mammalian cell culture or whole organisms. If the two proteins of interest interact, the fused reporter fragments are brought close together which allows the correct folding and reconstitution of the reporter protein ( Figure 1 ). The PCA technique has been successfully applied to several reporter proteins such as β-lactamase, dihydrofolate reductase, different fluorescent proteins, as well as Renilla, Gaussia and firefly luciferase [5] [6] [7] [8] [9] [10] [11] . In contrast with the yeast two-hybrid or split-ubiquitin system [12] , PCAs detect the reporter protein itself in situ and do not rely on the indirect detection of transcriptional activation of the reporter gene. This feature allows the application of PCAs in virtually every subcellular compartment and on both the cytosolic and the luminal/extracellular faces of organelle membranes. Application of the PCA technique to fluorescent proteins, also termed BiFC (bimolecular fluorescence complementation) [13] , is an especially attractive approach since fluorescent proteins are known to express, fold and fluoresce in almost every cell type and subcellular compartment. Furthermore, PCAs using fluorescent proteins are highly sensitive and trap even weak 
Luminal YFP (yellow fluorescent protein) PCA
We chose the citrine variant of YFP as a luminal PCA reporter. In the citrine variant, the glutamine residue at position 69 is replaced by methionine which improves the photostability and expression of YFP in subcellular compartments including the ER [15] . YFP-citrine was dissected into an N-terminal fragment (YFP fragment 1: residues 1-158 of YFP) and a C-terminal fragment (YFP fragment 2: residues 159-239 of YFP) as described by Remy et al. [16] . To reduce the steric constraints for YFP complementation, a 10-amino-acid flexible linker (GGGGSGGGGS) was introduced between the YFP fragments and the protein of interest. The luminal YFP PCA was assessed in a proof-of-concept study with the cargo receptor ERGIC-53 (endoplasmic reticulum-Golgi intermediate compartment protein of 53 kDa) [17] . ERGIC-53 is an oligomeric type I transmembrane protein that cycles in the early secretory pathway [18] together with its luminal interaction partner MCFD2 (multiple coagulation factor deficiency protein 2) [19] . The luminal domain of ERGIC-53 contains a mannose-specific CRD (carbohydrate recognition domain) which binds a subset of glycoproteins including cathepsin Z [20] , cathepsin C [21] and blood coagulation Factors V and VIII [22] . Using luminal YFP complementation, the oligomerization of ERGIC-53 and its interaction with MCFD2, cathepsin Z and cathepsin C were readily detected [17] . Importantly, the interaction between ERGIC-53 and cathepsin C, although suspected previously, was not detectable by any other method including co-immunoprecipitation and chemical cross-linking. The interaction of ERGIC-53 with blood coagulation Factors V and VIII could not be visualized due to too low expression levels of the blood coagulation Factor V and VIII fusion proteins. Figure 2 illustrates the mode of action of the luminal YFP PCA and visualizes the interaction of ERGIC-53 with MCFD2. Routinely, YFP complementation was analysed using two different readouts. As a first readout, single living cells were monitored using fluorescence microscopy as depicted in Figure 2 . As a second readout, YFP fluorescence of total cell populations was measured in a fluorimeter. The fluorimetric analysis of total cell populations results in a numerical output of YFP complementation which is essential whenever perturbations of protein-protein interactions are intended to be examined. As an example, we quantified the effect of MCFD2 on ERGIC-53 cargo-binding properties by applying the luminal YFP PCA in MCFD2-depleted cells [23] . Thereby MCFD2 was shown not to be required for the binding of cathepsin Z and cathepsin C to ERGIC-53 in vivo.
What about the specificity of the luminal YFP PCA? A concern is overexpression of the constructs. To avoid overexpression artefacts, we kept the expression time of the YFP PCA constructs to 24 h and monitored all expression levels by Western blotting. In the case of our ERGIC-53 YFP PCA constructs, expression levels were in the range of the endogenous protein which guaranteed specificity as demonstrated by two independent controls [17] . First, no YFP complementation was detected if an interaction was probed for ERGIC-53 and the unrelated unglycosylated secretory protein albumin. Secondly, inactivation of ERGIC-53's lectin domain by the N156A point mutation selectively decreased YFP complementation for the lectin-mediated interaction of ERGIC-53 and its cargo proteins cathepsin Z and cathepsin C, whereas the N156A mutation did not affect ERGIC-53 oligomerization or its interaction with MCFD2.
In conclusion, these results demonstrate that luminal YFP PCA is a simple, sensitive and specific assay that can be applied to transmembrane as well as soluble luminal proteins.
Future directions
An important feature of YFP complementation is its irreversibility [14] . Once folded, the stable β-barrel structure of YFP impedes the re-dissociation of the two YFP fragments. This clearly facilitates the capture of transient protein interactions, but complicates the analysis of dynamic protein complexes. A reversible and highly sensitive PCA has been developed recently, however, using Gaussia luciferase as the reporter protein [10] . It will be interesting to examine whether this luciferase-based PCA can be adapted to the lumen of the secretory pathway to monitor the dynamic proteinprotein interactions taking place during protein folding and modification.
In addition to characterizing already known or validate suspected protein interactions, the PCA technique can be applied to screen for novel protein-protein interactions. In 2004, a GFP (green fluorescent protein)-based PCA was used to screen a cDNA library for novel interaction partners of protein kinase B (PKB) [24] . To this end, a human brain cDNA library (prey) and PKB (bait) were tagged with fragments 1 and 2 of GFP respectively. Upon co-expression in mammalian COS cells, GFP-positive cells were isolated by FACS, prey plasmids were recovered and analysed, and Ft1 was identified as a novel interaction partner of PKB [24] . Using the screening procedure established by Remy and Michnick [25] , we are currently developing a luminal YFP PCA-based cDNA library screening strategy to search for novel cargo proteins of ERGIC-53. Our preliminary data suggest that luminal YFP PCA-based cDNA library screening is possible. YFP PCA-based genome-wide screening is a powerful emerging technique to map protein complexes in the secretory pathway.
